Document Detail

The thalidomide disaster, lessons from the past.
MedLine Citation:
PMID:  23138926     Owner:  NLM     Status:  In-Data-Review    
It is close to 60 years since thalidomide was created by the German company, Chemie-Grünenthal, and launched as "Contergan." This was soon to be followed in England by the launch of "Distaval." Of all the drugs developed in the intervening years, thalidomide has undoubtedly had the greatest influence on shaping the Pharmaceutical Industry as we know it today.Strong marketing pressure in an Industry hungry for new medicines brought an inadequately tested drug to the market, targeted outsourcing quickly expanded the client base and finally market forces prevented timely withdrawal, even when evidence was emerging of disastrous side-effects. The full story of thalidomide was told by the Sunday Times in "Suffer The Children" (Kingsley et al., Suffer the children: the story of thalidomide, the insight team of the Sunday times (UK), 1979).Many preventative measures have been taken in the intervening years in light of the lessons learned with thalidomide. However, many of the pressures that led to the thalidomide disaster exist today with record high management and shareholder pressures to achieve success, parallel worldwide marketing, increased numbers of targeted outsourcing by small companies forming alliances with "Big Pharma" and, according to some commentators, a breakdown in the system of checks and balances that have existed in the regulatory authorities in the intervening years.Using thalidomide as a point of reference, this chapter looks at drug development and testing, regulatory authorities and guidelines, outsourcing and in-licensing, pharmacovigilance, and factors that influence withdrawal of a drug from the market.
James E Ridings
Related Documents :
24286966 - Does treatment fidelity predict client outcomes in 12-step facilitation for stimulant a...
25418056 - Ingredients in fruit juices interact with dasatinib through inhibition of bcrp: a new m...
8272476 - Drug use and somatic illnesses with psychological component: a nation-wide survey among...
24238956 - "every 'never' i ever said came true": transitions from opioid pills to heroin injecting.
22443366 - The brain as a target for development of new class of drugs for the treatment of somati...
24714126 - Insights and ideas garnered from marine metabolites for development of dual-function ac...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Methods in molecular biology (Clifton, N.J.)     Volume:  947     ISSN:  1940-6029     ISO Abbreviation:  Methods Mol. Biol.     Publication Date:  2013  
Date Detail:
Created Date:  2012-11-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9214969     Medline TA:  Methods Mol Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  575-86     Citation Subset:  IM    
GlaxoSmithKline, Ware, UK,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reproductive toxicity risk assessment for pesticides.
Next Document:  MicroRNAs in brain metastases: big things come in small packages.